Search Results

Your search for Annick Desjardins, MD, FRCPC matches 2 pages

Showing 1 - 2

By Annick Desjardins, MD, FRCPC / February 1, 2014

An Overview of the REGAL Trial and Anti-VEGF Therapies in Recurrent Glioblastoma

As published in the Journal of Clinical Oncology by Batchelor and colleagues1 and reviewed in a recent issue of The ASCO Post (November 15, 2013, page 106), the REGAL trial was a randomized, phase III, placebo-controlled, partially blinded trial evaluating the efficacy of cediranib, an...

cns cancers

By Jo Cavallo / May 25, 2015

Will the PVS-RIPO Poliovirus Be a Game Changer in the Treatment of Recurrent Glioblastoma?

Although the idea of using viruses to target cancer cells dates back more than 100 years, technologic advances in the genetic engineering of viruses are now making it possible to safely test oncolytic virotherapy as a valid strategy against cancer cells. One type of genetically engineered virus...

Apr

Today In Oncology

Search Results

Your search for Annick Desjardins, MD, FRCPC matches 2 pages

An Overview of the REGAL Trial and Anti-VEGF Therapies in Recurrent Glioblastoma

Will the PVS-RIPO Poliovirus Be a Game Changer in the Treatment of Recurrent Glioblastoma?

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs